Metabolism - Clinical and Experimental
Volume 44, Issue 6 , Pages 745-748 , June 1995

Effect of combined administration of growth hormone (GH)-releasing hormone, GH-releasing peptide-6, and pyridostigmine in normal and obese subjects

  • F. Cordido

      Affiliations

    • Faculty of Medicine, University of Santiago de Compostela Santiago de Compostela, Spain
    • “Hospital Juan Canalejo,” La Coruña, Spain
    • ,
  • A. Peñalva

      Affiliations

    • Faculty of Medicine, University of Santiago de Compostela Santiago de Compostela, Spain
    • “Hospital Juan Canalejo,” La Coruña, Spain
    • ,
  • R. Peino

      Affiliations

    • Faculty of Medicine, University of Santiago de Compostela Santiago de Compostela, Spain
    • “Hospital Juan Canalejo,” La Coruña, Spain
    • ,
  • F.F. Casanueva

      Affiliations

    • Faculty of Medicine, University of Santiago de Compostela Santiago de Compostela, Spain
    • “Hospital Juan Canalejo,” La Coruña, Spain
    • ,
  • C. Dieguez

      Affiliations

    • Corresponding Author InformationAddress reprint requests to C. Dieguez, MD, PO Box 563, Santiago de Compostela, Spain.
    • Faculty of Medicine, University of Santiago de Compostela Santiago de Compostela, Spain
    • “Hospital Juan Canalejo,” La Coruña, Spain

Received 2 May 1994 ,Accepted 18 July 1994.

References 

  1. Momany FA, Bowers CY, Reynolds GA, et al.  Conformational energy studies and in vitro and in vivo activity data on growth hormone releasing peptide. Endocrinology. 1984;114:1531–1536
  2. Bowers CY, Momany FA, Reynolds GA, et al.  On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. Endocrinology. 1984;114:1537–1545
  3. Ilson BE, Jorkasky DJ, Curnow RT, et al.  Effect of a new synthetic hexapeptide to selectively stimulate growth hormone release in healthy human subjects. J Clin Endocrinol Metab. 1989;69:212–214
  4. Bowers CY, Reynolds GA, Durham D, et al.  Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone. J Clin Endocrinol Metab. 1990;79:975–982
  5. Peñalva A, Carballo A, Pombo M, et al.  Effect of growth hormone (GH)-releasing hormone (GHRH), atropine, pyridostigmine and hypoglycemia on GHRP-6-induced GH secretion in man. J Clin Endocrinol Metab. 1993;76:168–171
  6. DeBell WK, Pezzoli SS, Thorner MO. Growth hormone (GH) secretion during continuous infusion of GH-releasing peptide: Partial response attenuation. J Clin Endocrinol Metab. 1991;72:1312–1316
  7. Muruais J, Peñalva A, Dieguez C, et al.  Influence of endogenous cholinergic tone and alpha-adrenergic pathways on growth hormone responses to His-dTrp-Ala-Trp-dPhe-Lys-NH2 in the dog. J Endocrinol. 1993;138:211–218
  8. Bowers CY, Sartor AO, Reynolds GA, et al.  On the actions of the growth hormone-releasing hexapeptide GHRP-6. Endocrinology. 1991;128:2027–2035
  9. Clark RG, Carlsson LMS, Trojnar J, et al.  The effects of growth hormone releasing peptide and growth hormone releasing factor in conscious and anaesthetized rats. J Neuroendocrinol. 1989;1:1071–1080
  10. Walker RF, Codd EE, Barone FC, et al.  Oral activity of the growth hormone releasing peptide His-dTrp-Ala-Trp-dPhe-Lys-NH2 in rats, dogs, and monkeys. Life Sci. 1990;47:29–36
  11. Malozousky S, Hao EN, Ren SG, et al.  Growth hormone (GH) responses to the hexapeptide and GH-releasing hormone (GHRH) in the cynomolgus macaque: Evidence for non GHRH-mediated responses. J Clin Endocrinol Metab. 1991;73:314–317
  12. Peñalva A, Pombo M, Carballo A, et al.  Influence of sex, age and adrenergic pathways on GH responses to GHRP-6. Clin Endocrinol (Oxf). 1993;38:87–91
  13. Bowers CY. Novel GH-releasing peptides. In:  Melmed S editors. Molecular and Clinical Advances in Pituitary Disorders. Los Angeles, CA: Endocrine Research and Education; 1993;p. 153–158
  14. Bell JP, Donald RA, Espiner EA. Pituitary response to insulin-hypoglycemia in obese subjects before and after fasting. J Clin Endocrinol Metab. 1970;31:546–551
  15. Sims EAH, Danforth E, Horton E, et al.  Endocrine and metabolic effects of experimental obesity in man. Recent Prog Horm Res. 1973;29:457–463
  16. Copinschi G, Wegienka LC, Hane S, et al.  Effect of arginine on serum levels of insulin and growth hormone in obese subjects. Metabolism. 1967;16:485–491
  17. Glass AR, Burman KD, Dahms WT, et al.  Endocrine function in human obesity. Metabolism. 1981;30:89–104
  18. Finer H, Price P, Grossman A, et al.  The effects of enkephalin analogue on pituitary hormone release in human obesity. Horm Metab Res. 1987;19:68–70
  19. Cordido F, Dieguez C, Casanueva FF. Effect of central cholinergic enhancement by pyridostigmine on the GH secretion elicited by clonidine, arginine, or hypoglycemia in normal and obese subjects. J Clin Endocrinol Metab. 1990;70:1361–1370
  20. Williams T, Berelowitz M, Joffe SN, et al.  Impaired growth hormone responses to growth hormone releasing factor in obesity. N Engl J Med. 1984;311:1403–1407
  21. Kopelman PG, Noonan K. Growth hormone response to low dose intravenous injections of growth hormone releasing factor in obese and normal women. Clin Endocrinol (Oxf). 1986;24:157–164
  22. Cordido F, Casanueva FF, Dieguez C. Cholinergic receptor activation by pyridostigmine restores GH responsiveness to GHRH in obese subjects. J Clin Endocrinol Metab. 1989;68:290–293
  23. Cordido F, Peñalva A, Dieguez C, et al.  Massive GH discharge in obese subjects after the combined administration of GHRH and GHRP-6: Evidence for a marked somatotroph secretory capability in obesity. J Clin Endocrinol Metab. 1993;76:819–823
  24. Bray GA. Obesity in America. In: Washington, DC: US Government Printing Office, NIH Publications; 1977;p. 77–359
  25. Massara F, Ghigo E, Molinati P, et al.  Potentiation of cholinergic tone by pyridostigmine bromide re-instates and potentiates the GH responsiveness to intermittent administration of growth hormone releasing factor in man. Acta Endocrinol (Copenh). 1986;113:12–16
  26. Peñalva A, Muruais C, Casanueva FF, et al.  Effect of enhancement of endogenous cholinergic tone with pyridostigmine on the dose-response relationships of GHRH-induced GH secretion in normal subjects. J Clin Endocrinol Metab. 1990;70:324–328
  27. Locatelli V, Torsello A, Redaelli M, et al.  Cholinergic agonist and antagonist drugs modulate the growth hormone response to growth-hormone releasing hormone in the rat: Evidence for mediation by somatostatin. J Endocrinol. 1986;11:271–278
  28. Reynolds GA, Bowers CY, Granda-Ayala R, et al.  Dimensions of GH releasing peptides (GHRPs). In: Proceedings of the 75th Annual Meeting of the Endocrine Society. 1993;p. 413
  29. Pong SS, Chaung LYP, Smith RG, et al.  GHRP-6 stimulates GH secretion by depolarization in rat pituitary cell cultures. In: Proceedings of the 73rd Annual Meeting of the Endocrine Society. Bethesda, MD. Endocrine Society Press; 1991;p. 88
  30. Koch BD, Blalock JB, Schonbrunn A, et al.  Characterization of the cyclic AMP-independent actions of somatostatin in GH cells. I. An increase in potassium conductance is responsible for both the hyperpolarization and the decrease in intracellular free calcium produced by somatostatin. J Biol Chem. 1988;263:216–225

☆ Supported by grants from the Fondo de Investigacion Sanitaria, the Spanish Ministry of Health, and the Xunta de Galicia.

PII: 0026-0495(95)90187-6

Metabolism - Clinical and Experimental
Volume 44, Issue 6 , Pages 745-748 , June 1995

Article Tools